Comparison of measles virus-specific antibody titres as measured by enzyme-linked immunosorbent assay and virus neutralisation assay

We assessed whether measles virus-specific antibody levels in the Dutch population as estimated by an enzyme-linked immunosorbent assay (ELISA) were comparable with estimates by virus neutralisation assay (NT), prompted by a relatively low ELISA seroprevalence in the 10–21-year-old group. We tested...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2003-10, Vol.21 (27), p.4210-4214
Main Authors: van den Hof, Susan, van Gageldonk-Lafeber, Arianne B., van Binnendijk, Robert S., van Gageldonk, Pieter G.M., Berbers, Guy A.M.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age
Aged
Aging - immunology
Antibodies, Viral - analysis
Antibodies, Viral - biosynthesis
Biological and medical sciences
Child
Child, Preschool
Children & youth
Confidence intervals
ELISA
Enzyme-Linked Immunosorbent Assay
Enzymes
Female
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Humans
Immunization, Secondary
Infant
Male
Measles
Measles antibodies
Measles virus - immunology
Middle Aged
Molecular immunology
Monitoring, Immunologic
Netherlands - epidemiology
Neutralisation
Neutralization Tests
Population
Techniques
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We assessed whether measles virus-specific antibody levels in the Dutch population as estimated by an enzyme-linked immunosorbent assay (ELISA) were comparable with estimates by virus neutralisation assay (NT), prompted by a relatively low ELISA seroprevalence in the 10–21-year-old group. We tested 791 sera from individuals aged 2–49 years both in ELISA and NT. Seroprevalence in the 10–21-year-old group was 93.4% (95% confidence interval (CI) 89.5–97.2%) in ELISA versus 97.2% (CI 94.7–99.6%) in NT. There was good agreement between NT and ELISA seroprevalences in the vaccinated 2–9-year-olds and the unvaccinated 22–49-year-olds.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(03)00490-0